Clinical trial: The glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: A randomized, placebo-controlled, double-blind study

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 2, 2009, Pages 198-206

  Hellstrom P M ^a   Hein, J ^b   Bytzer, P ^c   BjOrnssOn E ^d   Kristensen, J ^e   Schambye, H ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c Mental Health Services CPH   (Denmark)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Rose Pharma   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; PLACEBO; ROSE 010; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; IRRITABLE COLON; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; VOMITING;

ADULT; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, SUBCUTANEOUS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 57649166909     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03870.x     Document Type: Article

References (35)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 91.
2. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007 56 : 1770 98.
3. Gralnek I, Hays R, Kilbourne A, Naliboff B, Mayer E. The impact of IBS on health-related quality of life. Gastroenterology 2000 119 : 654 60.
4. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000 46 : 78 82.
5. Russo MW, Gaynes BN, Drossman DA. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol 1999 29 : 339 43.
6. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003 18 : 671 82.
7. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006 24 : 21 37.
8. American College of Gastroenterology. Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002 97 : S1 5.
9. Dalrymple J, Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. Br Med J 2008 336 : 556 8.
10. Olden KW. Approach to the patient with severe, refractory irritable bowel syndrome. Curr Treat Options Gastroenterol 2003 6 : 311 7.
11. Kellow JE, Gill RC, Wingate DL. Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome. Gastroenterology 1990 98 : 1208 18.
12. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008 6 : 772 81.
13. Hellström PM, Grybäck P, Jacobsson H. The physiology of gastric emptying. Best Pract Res Clin Anaesthesiol 2006 20 : 397 407.
14. Näslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999 277 : R910 6.
15. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998 43 : 2284 90.
16. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002 282 : G424 31.
17. Andrews CN, Bharucha AE, Camilleri M, et al. Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. Am J Physiol Gastrointest Liver Physiol 2007 292 : G1359 65.
18. Hellström PM, Näslund E, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008 20 : 649 59.
19. Yu BS, Wang AR. Glucagon-like peptide 1 based therapy for type 2 diabetes. World J Pediatr 2008 4 : 8 13.
20. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003 10 : 2471 83.
21. Patterson B, Trautmann M, Mace K, Ernest C. The pharmacokinetics and pharmacodynamics of LY307161SR, a sustained release formulation of a GLP-analogue administered subcutaneously to patients with type 2 diabetes. Diabetologia 2002 45 (suppl 2 A43.
22. Trautmann M, Kapitza C, Mace K, Patterson B, Hompesch M, Heise T. LY307161SR a sustained release forumation of a GLP-1 analog is suitable for once daily administration in patients with type 2 diabetes. Diabetes Forecast 2002 51 (suppl 2 A135.
23. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999 45 : II43 7.
24. Wallenstein S. The VAS relief scale and other analgetic measures. Carry-over effects in parallel and cross-over studies In : Max M, Portenoy R, Laska E, eds. The Design of Analgesic Clinical Trials. New York : Raven Press, 1991 : 97 103.
25. Dorn SD, Kaptchuk TJ, Park JB, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007 19 : 630 7.
26. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005 17 : 332 40.
27. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005 3 : 237 47.
28. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, De Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2008 4.
29. Saad RJ, Chey WD. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs 2008 17 : 117 30.
30. Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol 2008 14 : 2639 49.
31. Ramadan NM. Assessing the efficacy of drugs for the acute treatment of migraine: issues in clinical trial design. CNS Drugs 2002 16 : 181 96.
32. Cain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006 101 : 124 32.
33. Pare P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006 28 : 1726 35.
34. Chang L, Toner BB, Fukudo S, et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006 130 : 1435 46.
35. Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998 10 : 415 21.